Non-cystic Fibrosis Bronchiectasis Clinical Trial
Official title:
The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis: A Randomised Controlled Trial
Number of Patients:
Study group - Bronchiectasis that is not attributable to Cystic fibrosis
- Group 1 - Pulmonary Rehabilitation
- Group 2 - Standard care
Sample size - 20 in each arm
Study Design:
- Randomised controlled trial (RCT)
All patients who qualify for the study will undergo a detailed evaluation. Baseline
assessment will include the following parameters:
- Anthropometry
- Pulmonary Function Tests and Respiratory muscle strength
- Cardiopulmonary Exercise Testing (CPET)
- Six Minute Walk Test (6MWT)
- Severity of dyspnoea (Dyspnoea scale)
- Limb muscle strength
- Inflammatory markers in the serum - C-reactive protein
- Quality of Life
Patients will then be randomized (using table of random numbers) to either the pulmonary
rehabilitation group or the standard arm group. After 8 weeks of pulmonary rehabilitation,
patients will again be reassessed by the aforementioned tools.
METHODOLOGY
Type of study - Randomised controlled trial (RCT)
Study period - March 2014 to July 2016
Place of study - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of
Medical Sciences, New Delhi
Study group - Bronchiectasis that is not attributable to Cystic fibrosis
- Group 1 - Pulmonary Rehabilitation (PR)
- Group 2 - Standard care
Sample size - 20 in each arm
The study requires patients to attend the pulmonary rehabilitation program twice a week for 8
weeks.
Consent will be taken from all patients prior to enrollment.
Exacerbations of bronchiectasis will be defined by the following criteria:
At least four of the following clinical signs and symptoms suggestive of an acute
exacerbation of bronchiectasis over two consecutive days:
- Increase in sputum quantity
- Change in sputum colour
- Change in sputum viscosity
- Increase in cough
- Increase in dyspnoea
- Increase in fatigue/lethargy
- Fever (self-reported)
- Episode of haemoptysis
The number of acute pulmonary exacerbations per year in the previous years will be recorded.
All patients attending the out patient department of pulmonary department of All India
Institute of Medical Sciences will be screened for recruitment in the study.
Baseline evaluation
All patients who qualify for the study will undergo a detailed evaluation. This will include
demographic data, complete medical history and clinical examination including anthropometry.
Baseline assessment will include the following parameters:
i. Anthropometry
ii. Pulmonary Function Tests and Respiratory muscle strength
iii. Cardiopulmonary Exercise Testing (CPET)
iv. Six Minute Walk Test (6MWT)
v. Severity of dyspnoea (Dyspnoea scale)
vi. Limb muscle strength
vii. Inflammatory markers in the serum - C-reactive protein
viii. Quality of Life
The participants will then be randomly assigned to receive either standard care alone or
pulmonary rehabilitation. The randomisation will be completed by the creation of a random
numbers table.
Intervention
Standard care group
Candidates randomized to the "standard care group" will receive standard care for
bronchiectasis according to current guidelines. These participants will receive instruction
and review of airway clearance therapy (ACT). Each participant will be provided with written
information about bronchiectasis and education regarding self-management of the condition.
Participants who have not been previously instructed in any ACT will be taught the active
cycle of breathing technique. These participants will not receive any supervised exercise
training.
Pulmonary rehabilitation group
Participants randomised to the Pulmonary Rehabilitation group will receive exercise training
and regular instruction in self-management of ACT along with standard care. Patients will be
enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine
and Sleep disorders, All India Institute of Medical Sciences.
The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise
training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one
will be at home. The patient will be asked to maintain a personal log recording the date,
time, duration and type of exercise performed to ensure compliance, and these will be
regularly reviewed and monitored.
The Rehabilitation Programme will include the following:
i. Patient education
ii. Exercise training
iii. Ventilator and breathing exercises
Outcome Assessment
The patients will be reassessed at the end of the 8 week training programme.
Primary outcome measures:
- Maximum exercise capacity - measured with the 6MWT (the primary outcome is the greatest
distance walked) and the CPET (VO2 max)
- HRQoL measured with the St. George Respiratory Questionnaire
Secondary outcome measures:
- Change in the Leicester Cough Questionnaire
- Change in the C- reactive protein
- Change in the lung Functions
- Change in the anxiety and depressions score
- Change in the hand grip dynamometry
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01792440 -
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT05523180 -
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
|
N/A | |
Completed |
NCT03218917 -
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Completed |
NCT05495243 -
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough
|
Phase 2 | |
Recruiting |
NCT06237348 -
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
|
N/A | |
Completed |
NCT03056326 -
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT02614300 -
The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
|
N/A | |
Recruiting |
NCT04322929 -
Roflumilast in Non-CF Bronchiectasis Study (2019)
|
Phase 2 | |
Completed |
NCT05369624 -
Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program
|
N/A | |
Completed |
NCT04010799 -
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
|
Phase 1 | |
Completed |
NCT03428334 -
Roflumilast in Non-CF Bronchiectasis Study
|
Phase 2 | |
Recruiting |
NCT06164470 -
Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT04656275 -
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
|
Phase 1 | |
Not yet recruiting |
NCT06151366 -
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
|
||
Completed |
NCT02081963 -
Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
|
Phase 4 | |
Completed |
NCT01792427 -
Mortality in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Recruiting |
NCT04278040 -
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Completed |
NCT05006573 -
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
|
Phase 3 | |
Not yet recruiting |
NCT06352944 -
Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
|
||
Recruiting |
NCT05860803 -
Breathing Training and Exercise Capacity in Non-CFB
|
N/A |